VEGFD Protein, Human, Recombinant (His)

Catalog No. TMPY-01008

VEGFD Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 13.6 kDa and the accession number is O43915.

VEGFD Protein, Human, Recombinant (His)

Catalog No. TMPY-01008

VEGFD Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 13.6 kDa and the accession number is O43915.

Pack Size	Price	Availability
10 μg	100 €	In Stock
20 μg	145 €	7-10 days
50 μg	229 €	7-10 days
100 μg	328 €	7-10 days
200 μg	555 €	7-10 days
500 μg	1.102 €	7-10 days

Bulk & Custom

Add to Cart

Questions

Select Batch

Resource Download

COA User Guide of Recombinant Proteins

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity	1.Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 0.3‑1.6 μg/mL. 2.Captured VEGFR3/FLT4 Protein, Human on proA Chip can bind VEGF-D with an affinity constant of 39.03 nM as determined in a SPR assay (Routinely tested).
Description	VEGFD Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 13.6 kDa and the accession number is O43915.
Species	Human
Expression System	HEK293 Cells
Tag	C-His
Accession Number	O43915
Synonyms	VEGF-D,VEGFD,c-fos induced growth factor (vascular endothelial growth factor D)
Construction	A DNA sequence encoding the mature form of human VEGFD (NP_004460.1) corresponding to amino acid (Phe 93-Ser 201) was expressed with a C-terminal polyhistidine tag. Predicted N terminal: Phe 93
Protein Purity	> 95 % as determined by SDS-PAGE.
Molecular Weight	13.6 kDa (predicted); 20-22 kDa (reducing condition, due to glycosylation)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Vascular endothelial growth factor D (VEGF-D), also known as C-fos induced growth factor (FIGF), belongs to the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. FIGF protein is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. FIGF protein is secreted as a non-covelent homodimer in an antiparallel fashion. Human FIGF protein is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. FIGF protein is structurally and functionally similar to VEGF-C. Therefore, FIGF protein binds and activates VEGFR-2 (Flk1) and VEGFR-3 (Flt4) receptors, and may particularly be involved in cancers, such as breast cancer, epithelial ovarian carcinoma and so on.